Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation

Ziel

The gut microbiome is a key regulator of human immunity, shaping responses to infection, vaccination, and cancer. Population-level differences in microbiome composition and function have been linked to variable vaccine efficacy, yet the mechanisms remain poorly understood. During defined physiological or clinical windows, the equilibrium between host and microbiome becomes particularly vulnerable, and transient perturbations can durably imprint on immune function and disease risk. Hematopoietic stem cell transplantation (SCT), a cornerstone therapy for hematologic cancers such as multiple myeloma (MM), represents one such scenario, marked by profound microbiome disruption, immune reconstitution, and the need for re-vaccination. MM patients often mount poor vaccine responses and experience infection-related morbidity. This setting uniquely enables the investigation of host-microbiome-vaccine interactions in a controlled yet physiologically authentic context, offering insights unattainable in healthy adults.
Through MicroMM, I will define how microbiome perturbations during SCT shape immune recovery, vaccine responsiveness, and clinical outcome in MM patients. Leveraging a longitudinal cohort, I will integrate functional microbiome analyses, high-resolution immune profiling, and serial vaccine monitoring, focusing on vaccines with known variability post-SCT. Advanced computational modeling will identify microbiome signatures predictive of vaccine efficacy and immune resilience. To establish causality, mechanistic studies in gnotobiotic mice colonized with patient-derived microbiomes will dissect microbial contributions to immune imprinting, vaccine performance, and tumor control. By bridging clinical observation with mechanistic experimentation, MicroMM will uncover fundamental principles of microbiome-driven immune modulation and define actionable biomarkers to improve vaccine responsiveness and immune resilience in at-risk populations.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC - HORIZON ERC Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-STG

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

TECHNISCHE UNIVERSITAET MUENCHEN
Netto-EU-Beitrag
€ 1 060 873,00
Adresse
Arcisstrasse 21
80333 Muenchen
Deutschland
Region
Bayern Oberbayern München, Kreisfreie Stadt
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 1 060 873,00

Begünstigte (2)